Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

COVID-19 Vaccination Might Induce Reversible Cerebral Vasoconstriction Syndrome Attacks: A Case Report

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.

OriginalsprogEngelsk
Artikelnummer823
TidsskriftVaccines
Vol/bind10
Udgave nummer5
ISSN2076-393X
DOI
StatusUdgivet - 23 maj 2022

ID: 78297139